In this segment, Dr. Rodriguez describes studies she conducted on lymphoma treatments in collaboration with Dr. Cabanillas. She first explains a study that showed the efficacy of ifosfamide among patients who did not respond to the CHOP treatment. She next talks about use of the same drug for patients awaiting stem cell transplantation. This study is still in regular use. Dr. Rodriguez then says that the current atmosphere at MD Anderson focuses on developing new drugs rather than optimizing older drugs. As an example of the value of retaining older ideas, she mentioned work by Dr. Wilson that shows that continuous infusion of drugs is more effective than bolus administration, an idea that Dr. Cabanillas originally explored.https://open...
In this chapter, Dr. Benjamin talks about his research focus on sarcoma treatments, neoadjuvant ther...
Dr. Buzdar begins by talking about how he came to leave New England (where his wife, Barbara, was ve...
The subject of research in the 1980s leads Dr Bruner to describe how some MD Anderson faculty began ...
In this segment, Dr. Rodriguez describes studies she conducted on lymphoma treatments in collaborati...
In this segment, Dr. Rodriguez sketches how she began to shift away from research as her main focus....
Dr. Alexanian discusses the transplant supported program in myeloma. He sketches the history of the ...
In this chapter, Dr. Alexanian talks about the treatments he innovated using thalidomide. He explain...
To begin this segment, Dr. Rodriguez sketches her research while a Fellow at the University of Arizo...
Dr. Elting explains how her study of thrombosis in cancer patients enabled her to establish a new re...
Dr. Gehan recollects Dr. R. Lee Clark’s approach to funding, recruitment, and management and the att...
In this chapter, Dr. Benjamin explains that he spent his first two years at MD Anderson establishing...
In this chapter, Dr. Buzdar sketches his evolving research focus within the Breast Cancer Section. ...
Dr. Freireich explains why the slow evolution of the blood separator made it necessary for him to le...
Dr. Alexanian discusses his work with erythropoeinin and its impact. He then talks about how myeloma...
Dr. Cox describes the research he undertook when left the position of Vice President for Patient Car...
In this chapter, Dr. Benjamin talks about his research focus on sarcoma treatments, neoadjuvant ther...
Dr. Buzdar begins by talking about how he came to leave New England (where his wife, Barbara, was ve...
The subject of research in the 1980s leads Dr Bruner to describe how some MD Anderson faculty began ...
In this segment, Dr. Rodriguez describes studies she conducted on lymphoma treatments in collaborati...
In this segment, Dr. Rodriguez sketches how she began to shift away from research as her main focus....
Dr. Alexanian discusses the transplant supported program in myeloma. He sketches the history of the ...
In this chapter, Dr. Alexanian talks about the treatments he innovated using thalidomide. He explain...
To begin this segment, Dr. Rodriguez sketches her research while a Fellow at the University of Arizo...
Dr. Elting explains how her study of thrombosis in cancer patients enabled her to establish a new re...
Dr. Gehan recollects Dr. R. Lee Clark’s approach to funding, recruitment, and management and the att...
In this chapter, Dr. Benjamin explains that he spent his first two years at MD Anderson establishing...
In this chapter, Dr. Buzdar sketches his evolving research focus within the Breast Cancer Section. ...
Dr. Freireich explains why the slow evolution of the blood separator made it necessary for him to le...
Dr. Alexanian discusses his work with erythropoeinin and its impact. He then talks about how myeloma...
Dr. Cox describes the research he undertook when left the position of Vice President for Patient Car...
In this chapter, Dr. Benjamin talks about his research focus on sarcoma treatments, neoadjuvant ther...
Dr. Buzdar begins by talking about how he came to leave New England (where his wife, Barbara, was ve...
The subject of research in the 1980s leads Dr Bruner to describe how some MD Anderson faculty began ...